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Autoimmunity and the Liver: 
Translation  to the clinic
type 1: adults and children 
Autoimmune Hepatitis
type 2: mainly children
 adults: often chronic, mild/moderate 
severity
 children/young adults: often acute, 
aggressive
Autoimmune Hepatitis
Presentation
 type 1 (ANA/SMA positive): 2/3 
 type  2 (LKM1 positive):       1/3
Juvenile Autoimmune Hepatitis
Juvenile Autoimmune Hepatitis
 females: 75%
Similarities between Type 1 and Type 2 AIH
 associated AI disorders: 20%
 family history of AI disease: 40%
 high IgG: 80%
 at a younger age 
Differences between Type 1 and Type 2 AIH
LKM1 positive AIH presents:
Juvenile Autoimmune Hepatitis
 with partial IgA deficiency 
 less frequently with cirrhosis
 more frequently with acute 
hepatic failure 
~ 50% of children/adolescents 
with AIH-1 serology have an 
overlap syndrome with 
sclerosing cholangitis
Juvenile Autoimmune Hepatitis
Autoimmune Sclerosing
Cholangitis
Autoimmune sclerosing cholangitis
 autoantibodies (ANA/SMA)
 high IgG
Diagnostic Criteria
 interface hepatitis
 abnormal cholangiogram
Gregorio et al, Hepatology 2001;33:544-553
 GGT and AP often normal at presentation
 particularly high IgG levels
 frequently associated with IBD
(sometimes asymptomatic)
Autoimmune sclerosing cholangitis
 affects equally males and females
 frequent positivity for ANCA
 elevated transaminases
 positive autoantibodies:    ANA/SMA (titre ≥ 1:20) = AIH-1 or ASC
anti-LKM1 (titre ≥ 1:10), anti-LC1 = AIH-2
 elevated IgG
 liver biopsy: interface hepatitis/multilobular collapse
 exclusion of viral hepatitis, Wilson disease, NASH
 cholangiogram (MRCP, ERCP):  normal = AIH; abnormal = ASC
Juvenile Autoimmune Liver Disease
Diagnostic criteria
treatment
Autoimmune Hepatitis
 normal transaminase levels
AIH – Definition of remission
 normal IgG levels
adults
 negative/<1:20 ANA/SMA
negative anti-LKM1
children/
adolescents
+
standard treatment:
AIH – All presentations*
(excluding fulminant liver failure)
* including acute liver failure with no or < grade 2 encephalopathy
 prednisolone
 azathioprine
fulminant liver failure   ► transplant
 30 mg prednisone + 1–2 mg/Kg azathioprine/day
 prednisone monotherapy 40-60 mg/day
Adulthood AIH 
AASLD Guidelines 
or
AASLD Guidelines, Hepatology 2010; 51:2193-213
AIH - Azathioprine (steroid-sparing agent)
Azathioprine can be hepatotoxic: 
not advisable as first line Rx in ill, jaundiced patients
particularly if cirrhotic
Adulthood AIH
 2 mg/Kg/day (maximum 60 mg/day)
Juvenile AIH
Prednisolone
 gradually decreased over 4-8 weeks
to 2.5-5 mg/day depending on age 
+ UDCA if ASC
(15 mg/Kg/day)
Juvenile AIH
Azathioprine
 add if high steroid dose required to maintain 
normal or nearly normal AST
or in the presence of serious steroid side effects
 myelosuppressive: start at low dose (0.5 mg/Kg/day) 
and increase gradually to 2 mg/Kg/day
 hepatotoxic: never first line Rx in ill, jaundiced
patients
 weekly LFTs, INR, FBC
‘Fine tuning’ to avoid severe side effects:
 aim to 80% AST decrease within 6 weeks
Juvenile AIH 
Rx schedule at King’s
80% ultimately 
require azathioprine
Juvenile AIH
 sustained remission on azathioprine
monotherapy (Johnson et al, New Engl J Med 1995;333:958)
 successful in ANA/SMA+ AIH
 less successful in LKM1+ AIH
In children:
In adults:
AIH - Maintenance of remission
King’s criteria for stopping treatment*
 at least one further year of normal LFTs & IgG,
negative or low titre autoantibodies (checked 3 monthly)
* never just before or during puberty
Juvenile AIH
 no inflammation on liver biopsy performed at the end 
of the year 
 gradual discontinuation of azathioprine, then prednisolone
 daily treatment for at least three years
13-year (8-29) follow up – Transplant-free survival
AIH vs ASC
Scalori et al, Hepatology 2007;46 Suppl 1:555A
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Outcome (King’s prospective study)
recurrence post LT 0% 0% 71%  
LT rate 27%14%6%
AIH vs ASC
progression of liver disease and 
recurrence post transplant  are 
associated to 
active inflammatory bowel disease
Autoimmune sclerosing cholangitis
King’s prospective study
Alternative treatments
Autoimmune Hepatitis
 for difficult-to-treat patients
 for induction of remission
Induction of remission
Alvarez et al, J Hepatol 1999;30:222
 6-month CyA priming in AIH-1 followed by pred + aza:
uncontrolled study, benefits unclear
 budesonide 3mg/tds + aza vs prednisone 40mg/od + aza
Budesonide - AIH
Manns et al. Gastroenterology 2010;39:1198-206
 budesonide 3 mg tds, decreased upon response
Multicentre European Study - Study design
azathioprine 1-2 mg/Kg +
 prednisone 40 mg once daily reduced per protocol
irrespective of response
 for 6 months, then budesonide to all for further 6 months
versus
Woynarowski et al. J Pediatr;163:1347-1353
Manns et al. Gastroenterology 2010;39:1198-206
normal transaminase levels 
without steroid side effects
Definition of response
Budesonide - AIH
Woynarowski et al. J Pediatr;163:1347-1353
 budesonide: 60% remission
 prednisone: 39% remission 
European multicentre study - 203 pts
Manns et al, Gastroenterology 2010;139:1198-206
Budesonide - AIH
budesonide prednisone 
6 months 15%16%
12 months 42%*50%*
Woynarowski et al. J Pediatr;163:1347-1353
complete response
Paediatric cohort - 46 patients, 10-18 yr
Multicentre European Study
Budesonide – Juvenile AIH
* compared to ~90% with King’s protocol
Aw et al, J Hepatol 2009;51:156
Difficult-to-treat patients: resistant or unresponsive
 Calcineurin inhibitors
anecdotal experience
 Rituximab
 anti-TNFα
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Adulthood AIH
Adulthood AIH
Adulthood AIH
